---
title: "Genmab A/S reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-13 01:37:02"
summary: "Genmab A/S reported quarterly adjusted earnings of DKK59.64​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of DKK9.67. The mean expectation of eleven analysts for the quarter was for earnings of DKK25.52 per share. Wall Street expected results..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Genmab A/S reported quarterly adjusted earnings of DKK59.64​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of DKK9.67. The mean expectation of eleven analysts for the quarter was for earnings of DKK25.52 per share. Wall Street expected results to range from DKK22.54 to DKK28.80 per share.
* Revenue rose 37.7% to DKK6.44 billion from a year ago; analysts expected DKK6.41 billion.
* Genmab A/S's reported EPS for the quarter was DKK59.64​.
* The company reported quarterly net income of DKK3.85 billion.
* Genmab A/S shares had fallen by 8.0% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 4% in the last three months.​
* In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Genmab A/S is DKK2,350.00

This summary was machine generated from LSEG data February 12 at 05:36 p.m. UTC. ​All figures in Danish crowns unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | 25.52 | 59.64 | Beat |
| Sep. 30 2024 | 21.89 | 19.81 | Missed |
| Jun. 30 2024 | 20.56 | 21.70 | Beat |
| Mar. 31 2024 | 11.83 | 20.18 | Beat |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P3251:0-genmab-a-s-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
